

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors in the order listed on Form Page 2. Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Cynthia Knox	POSITION TITLE Clinical Research Team Lead Supervisor Mary Bird Perkins Our Lady of the Lake Cancer Center
eRA COMMONS USER NAME (credential, e.g., agency login)	

EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable.)

INSTITUTION AND LOCATION	DEGREE (if applicable)	MM/YY	FIELD OF STUDY
Louisiana State University, Baton Rouge, LA	BS	1988	Psychology
Louisiana State University, Baton Rouge, LA	MBA	1990	Business Administration
Louisiana State University Medical Center, New Orleans, LA	BSN	1996	Nursing

A. Personal Statement

I have been a registered nurse for the past sixteen years and have not held a more meaningful position than the one in which I currently find myself. The experiences I have gained throughout my professional life have served as building blocks to get me to where I am today in my career. I have had experience in business, hospital floor nursing, special procedures nursing, home health nursing and research nursing. I have learned more in the past 5 years as a research nurse than in all the years prior that I worked in nursing. As a research nurse, and now as a research department supervisor, I have come to have a new appreciation for the entire research process. I have learned how complex the process is from the development of an idea to that idea being tested, tried and hopefully implemented as a new standard of care. I have participated in the following research related activities: consenting and enrolling patients, following patients throughout the clinical trial process, submitting required data, coordinating research related events with physicians, and attending national group meetings. In addition, I developed and conducted a seminar for our program’s patient navigators to educate them on the clinical trial process. I actively participate in our cancer program’s bi-weekly Tumor Conferences. At these conferences I provide discussion as it relates to current clinical trials that are open and could potentially be an option for patients being presented. I have also promoted clinical trials at our monthly Multi-Disciplinary Care Team meetings.

Mary Bird Perkins has been involved in the NCCCP since I started working in research. Being a part of this grant has provided me with additional insight into how important it is to include the minority and underserved populations in clinical trials. I have learned how significant it is to capture data as it relates to the NCCCP Screening and Accrual Logs. I have also participated in educating the minority and underserved populations through community outreach events. At these events, I was able to promote clinical trials available at our cancer center and educate attendees about the clinical trial process. A crucial component of the proposed venture is Cancer Care Delivery Research. The experience I have obtained through participating in the clinical research arena has prepared me well to be able to contribute as an integral member of our proposed NCORP team.

B. Positions and Honors

Positions and Employment

- 2012 – Clinical Research Team Lead Supervisor, Mary Bird Perkins - Our Lady of the Lake Cancer Center
- 2008 – 2012 Clinical Research Nurse, Mary Bird Perkins Cancer Center

2006 – 2008 Home Health Nurse, Woman's Hospital, Baton Rouge, LA
1998 – 2006 Special Procedures Nurse, Our Lady of the Lake, Regional Medical Center, Baton Rouge, LA
1997 – 1998 Oncology Unit Nurse, Our Lady of the Lake Regional Medical Center, Baton Rouge, LA
1995 – 1996 Nurse Tech, Touro Infirmary, New Orleans, LA
1991 – 1995 Assistant Controller, Costal Terminal Systems, Inc., Metairie, LA

Other Experience and Professional Memberships

2010 - Oncology Nursing Society
2010 - Baton Rouge Oncology Nursing Society
2012 - Association of Clinical Research Professionals

Certifications

2012 - Certified Clinical Research Professional
2014 - Oncology Certified Nurse

C. Selected Peer-reviewed Publications

None

D. Research Support

MBPCC-PS-1204 (Celldex) Olson (PI) 5/16/2012 -
Vaccine therapy among newly diagnosed glioblastoma patients.
The primary objective of the study is to confirm that the addition of rindopepimut/GM-CSF to adjuvant temozolomide improves overall survival in patients with newly diagnosed EGFRvIII positive glioblastoma who have undergone gross-total resection.

KLT_PANC-001 Bienvenu (PI) 6/3/2013 -
Advanced pancreatic cancer.
The goal of this study is to compare the effect of gemcitabine + Kanglaite Injection (KLTi) to gemcitabine alone in patients with locally advanced or metastatic pancreatic cancer, not amenable to curative surgical resection.

PH3-01 (Present) Spell (PI) 12/20/2011 -
Vaccine therapy in early stage HER2 low breast cancer.
The primary objective is to compare the disease-free survival (DFS) in subjects with operable early-stage, node-positive breast cancer who receive standard of care multimodality therapy plus NeuVax with rhGM-CSF as the treatment group or standard of care multimodality therapy plus the placebo with the vaccine adjuvant, rhGM-CSF (sargramostim) as the control group.

NSABP B-43 Veith (PI) 12/19/2009 -
HER2-Positive Ductal Carcinoma In Situ
The primary aim of this trial is to determine whether trastuzumab given concurrently with radiation therapy is more beneficial in preventing subsequent ipsilateral breast cancer recurrence, ipsilateral skin cancer recurrence, or ipsilateral DCIS, when compared with radiation therapy alone in women with HER2-positive ductal carcinoma in situ (DCIS) resected by lumpectomy.

RTOG 1008 Veith (PI) 10/18/2011 -
Malignant salivary gland tumors.
Acquire preliminary efficacy data comparing postoperative radiotherapy alone to concurrent chemotherapy and radiation using weekly cisplatin.

CALGB 80702 Veith (PI) 6/22/2010 -
Resected Stage III Colon Cancer.
To compare disease-free survival of patients with stage III colon cancer randomized to standard chemotherapy only (FOLFOX) or standard chemotherapy (FOLFOX) with 3 years of celecoxib 400 mg daily.

ECOG E3F05 Veith (PI) 2/9/2011 -
Symptomatic or progressive low grade gliomas.
To determine whether the addition of temozolomide to fractionated radiotherapy improves the progression-free survival (PFS) and median overall survival (OS) of patients requiring treatment for low-grade gliomas.

TALC McWhorter (PI) 7/28/2011 -
Laryngeal cancer observational study.
The immediate goals of this study are to compare the impact of primary chemoradiation versus surgery on patients with new tumors of the hypopharynx and cartilage-invading larynx) that would require total laryngectomy for cure.

MCC14690 (Total Cancer Care) Vincent (PI) 10/01/2008 -
Created a clinical data and tissue repository.
The overall objective of this study is to develop an improved standard of cancer care by facilitating new clinical trials, new technology, new informatics solutions and "personalized medicine."
TCGA (Total Cancer Genome Atlas Project) Vincent (PI) 09/2013 -
Biospecimen procurement program.
The TCGA project is designed to try to identify all of the genetic changes that can cause cancer in people by studying the genetic and biochemical material from various types of cancer tissue collected.

Connect CLL Bienvenu (PI) 4/27/2010 -
Chronic Lymphocytic Leukemia Disease Registry
Describe practice patterns of first-line therapy regimens and subsequent therapeutic strategies in patient initiated on therapy for CLL, as well as initiated on second line and subsequent therapies, in the community and academic setting.

Completed Research Support

NCIC MA.32 Veith (PI) 11/10/2010 - 1/23/2013
Early stage breast cancer.
To compare invasive disease free survival (IDFS) between subjects treated with metformin (850 mg po bid for 5 years) versus placebo in addition to standard adjuvant therapy.

CCCWFU 98110 Veith (PI) 2/11/2011 - 11/18/2013
Erectile dysfunction.
To determine the "best dose" of ArginMax to be used in a subsequent Phase III trial.

NLG-0405 Bienvenu (PI) 5/11/2012 - 9/17/2013
Surgically resected pancreatic cancer.
To assess overall survival after treatment with a regimen of adjuvant therapy (gemcitabine alone or with 5-FU chemoradiation) with or without HyperAcute®-Pancreas (algenpantucel-L) immunotherapy in subjects who have undergone surgical resection.

DFCI (Young & Strong) Schmeckle (PI) 10/25/2012 - 9/12/2013
Young women with breast cancer.
The overall objective of this study is to determine the effect of an education and support intervention for young women with breast cancer and their oncology providers (YWI) on attention to fertility issues

Program Director/Principal Investigator (Last, First, Middle):

compared to a physical activity comparison intervention (PAI) in a randomized controlled trial.

SWOG S0702 Veith (PI) 6/25/2013 - 12/13/2013

Incidence of osteonecrosis of the jaw in patients receiving Zometa.

The primary objective of this study is to prospectively assess the cumulative incidence of osteonecrosis of the jaw (ONJ) at 3 years in cancer patients with bone metastasis receiving zoledronic acid treatment.

MBPCC-PS 11-04 (Sciclone) Bienvenu (PI) 7/25/2011 - 7/29/2013

Oral Mucocitis

The goal of this study is to evaluate the efficacy and safety of three different doses of SCV-07 in attenuating oral mucositis in patients with Head & Neck cancers receiving concurrent chemotherapy and radiotherapy.